An Actelion

company: Shire was willing to pay 160 Swiss francs a share for Actelion, the sources said, a hefty premium to the stock Friday closing price of 132 francs, according to Euro News. Asked by Reuters for comment, a spokeswoman for Shire said the company did not comment on speculation. An informal approach by Shire was rebuffed several weeks ago, the newspaper said, citing financial industry sources. An Actelion spokesman said the company did not comment on market rumours. At the time, the company chief executive told Reuters it had not received any outside interest to buy the company. Earlier this year, Actelion raised its full-year guidance after strong sales of its new heart and lung drug helped its first-quarter earnings exceed analysts’ estimates. (news.financializer.com). As reported in the news.

The content, information, trademarks and multimedia posted on this blog copyrights to their original owners and herein blogged in good faith for the purpose of commentary, speech, opinion and debate.

financializer news

A weblog highlighting financial topics making news in the international media.